A recent meta-analysis82 that included 6 CVOTs of patients with diabetes and 4 CVOTs of patients with and without diabetes found that eGFR did not alter the relative benefit of SGLT2 inhibitors for MACE and heart failure outcomes;2,77,81,83–85 however, a greater relative benefit was reported for MACE in those with higher baseline albuminuria (ACR>300 mg/g HR 0.74 [95%CI 0.66, 0.84]; ACR 30-300 mg/g HR 0.95 [95%CI 0.82, 1.10]) ACR<30 mg/g HR 0.87 [95%CI 0.77, 0.98]). Here, SLC5A2 is linked to heart failure.